Distrofia oculofaríngea: primeros casos confirmados por biología molecular
Autores: Politei Juan Manuel1, Herrera Mariana2, Bernath Viviana2, Igarreta Pilar2, Zalar Alberto3
1: SECCION ENFERMEDADES NEUROMUSCULARES, INSTITUTO NEUROCIENCIAS, FUNDACION FAVALORO. Bs As Argentina
2: LABORATORIO GENDA, Sección Biología molecular, Bs As, Argentina
3: SERVICIO GASTROENTEROLOGIA, HOSPITAL JUAN FERNANDEZ, Bs As, Argentina
Autor Principal (RESPONSABLE): POLITEI JUAN MANUEL: jpolitei@hotmail.com
Sección Enfermedades Neuromusculares Fundación Favaloro. Presidente Luis Saenz Peña 265, Cap Fed, Buenos Aires, Argentina. CP 1110
1. Hill M, Creed G, McMullan T, Tyers A, Milton-Jones D, Robinson D, et al. Oculopharyngeal muscular dystrophy, phenotypic and genotypic studies in a UK population. Brain 2001; 124: 522-526.
2. Pou Serradel A, Lloreta Trull J, Corominas Torres J, Hommouda E, Urtizberea J, Richard P, et al. Distrofia muscular oculofaríngea: estudio de pacientes pertenecientes a siete familias españolas con diferentes expansiones GCG en el gen PABP2. Neurología 2004; 19: 239-247.
3. Rodríguez M, Camejo C, Bertoni B, Braida C, Rodríguez M, Brais B, et al. GCG founder mutation in the PABPN1 gene of OPMD Uruguayan families. Neuromuscul Disord 2005; 15: 185-190.
4. Lopez de Munain A, Goikoetxea M. Distrofia muscular oculofaringea: del paradigma de las mutaciones dinâmicas al de las proteinopatías tóxicas. Neurología 2004; 19: 235-238.
5. van der Sluijs B, van Engelen B, Hoefsloot L. Oculopharyngeal muscular dystrophy due to a small duplication in the PABPN1 gene. Hum Mutat. 2003;21:553
6. Wong V, Beckingsale P, Oley C, Sullivan T. Management of myogenic ptosis. Ophtalmology 2002;109: 1023-1031
7. Jasinska A, Michlewski g, Mezer M, Sobczak K, Kozlowski P, Napierala M, et al. Structures of trinucleotide repeats in human transcripts and their functional implications. Nucleid Acid Res 2003; 31: 5463-5468.
8. Brown L, Brown S. Alanine tracts: the expanding story of human illness and trinucleotide repeats. Trends Genet 2004; 20: 51-8.
9. Brais B, Bouchard J, Xie Y, Rochefort D, Chretein N, Tomé F, et al. Short GCG expansions in tha PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998; 18 :164-167.
10. Lovestone S, McLoughlin D. Protein aggregates and dementia : is there a common toxicity?. J Neuron Neurosurg Psychiatry 2002; 72: 152-161.
11. Hino H, Araki K, Uyama E, Takeya M, Araki M, Yoshinobu K, et al. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy. Hum mol Genet 2004; 13: 181-190.
12. Probst A, Tackmann W, Stoeckli H, Jerusalem F, Ulrich J. Evidence of chronic axonal atrophy in oculopharyngeal muscular dystrophy. Acta Neuropathol 1982; 57: 209-216.
13. Krause K, Schmitt H, Hartmann A. Okulopharyngeale muskeldystrophie mit neurogener muskelatrophie. Nervenarzt 1981; 52: 79-84.
14. Bilgen C, Bilgen I, Sener R. Oculopharyngeal muscular dystrophy: clinical and CT findings. Comput Med Imaging Graph 2001; 25: 527-529.
15. Munitiz V, Ortiz A, Martinez de Haro LF, Glover G, Ferri B, Montoya M, et al. Diagnosis and treatment of oculopharyngeal dystrophy: a report of three cases from the same family. Dis Esophagus. 2003;16:160-164.
16. Hill M, Hughes T, Milford C. Treatment for swallowing difficulties (dysphagia) in chronic muscle disease. Cochrane Database Syst Rev. 2004; (2):CD004303.
17. Duranceau CA, Letendre J, Clermont RJ, Levesque HP, Barbeau A. Oropharyngeal dysphagia in patients with oculopharyngeal muscular dystrophy. Can J Surg. 1978; 21:326-9.
18. Fradet G, Pouliot D, Robichaud R, St-Pierre S, Bouchard JP. Upper esophageal sphincter myotomy in oculopharyngeal muscular dystrophy: long-term clinical results. Neuromuscul Disord. 1997;7 Suppl 1:S90-5.
19. Mathieu J, Lapointe G, Brassard A, Tremblay C, Brais B, Rouleau GA, et al. A pilot study on upper esophageal sphincter dilatation for the treatment of dysphagia in patients with oculopharyngeal muscular dystrophy. Neuromuscul Disord. 1997;7 Suppl 1:S100-4.
20. Blitzer A, Brin MF. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol Head Neck Surg. 1997; 116: 328-30.
21. Rodrigue D, Molgat YM. Surgical correction of blepharoptosis in oculopharyngeal muscular dystrophy. Neuromuscul Disord. 1997; 7 Suppl 1:S82-4.
22. Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O''''Donovan DG, Rubinsztein DC. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med. 2005;11:672-7.
23. Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet. 2006;15:23-31.
24. Perie S, Mamchaoui K, Mouly V, Blot S, Bouazza B, Thornell LE, et al. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation. Neuromuscul Disord. 2006 ;16:770-81.
Comentarios
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.
